European Patent Office

T 0967/18 (Cancer therapy/BIOTEMPUS) du 14.03.2023

Identifiant européen de la jurisprudence
ECLI:EP:BA:2023:T096718.20230314
Date de la décision
14 mars 2023
Numéro de l'affaire
T 0967/18
Requête en révision de
-
Numéro de la demande
09007539.1
Langue de la procédure
Anglais
Distribution
Non distribuées (D)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Titre de la demande
Cancer therapy
Nom du demandeur
Biotempus Pty Ltd
Nom de l'opposant
Bristol-Myers Squibb Company
Chambre
3.3.04
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 104(1)European Patent Convention Art 106(1)European Patent Convention R 115(2)European Patent Convention R 142(1)(b)Rules of procedure of the Boards of Appeal 2020 Art 012Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)Rules of procedure of the Boards of Appeal 2020 Art 015(3)Rules of procedure of the Boards of Appeal 2020 Art 016
Mots-clés
Admissibility of appeal - (no)
Apportionment of costs - severe negligence (no)
Amendment after summons - exceptional circumstances (yes)
Exergue
Where opposition proceedings have been interrupted under Rule 142(1)(b) EPC, acts done by the parties or the competent body of the EPO during the period of interruption are considered invalid.
An appeal against a decision taken during the interruption is inadmissible, because it has no valid subject eligible for a judicial review.
The RPBA also apply to requests for apportionment of costs under Article 104(1) EPC.
A negligent behaviour may also justify apportionment of costs. However, the negligence must be serious enough to be considered equivalent to wilful misconduct.
Affaires citantes
-

Order

For these reasons it is decided that:

- The appeal is inadmissible.

- The requests of the respondent (opponent) and the appellant (patent proprietor) for a different apportionment of costs under Article 104 EPC are refused.